Journal of Diagnostics Concepts & Practice >

2025 , Vol. 24 >Issue 03: 263 - 267

DOI: https://doi.org/10.16150/j.1671-2870.2025.03.004

Academic trend at home and abroad

Issues and solutions in integrated radionuclide diagnosis and treatment

  • HONG Yena ,
  • ZHANG Yü ,
  • SHI Kuangyu ,
  • LI Biao ,
  • GUO Rui
Expand
  • 1. Department of Nuclear Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2. Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern 3010, Switzerland

Received date: 2024-11-04

  Accepted date: 2025-02-08

  Online published: 2025-06-25

Fold

Abstract

The integration of radionuclide diagnosis and treatment combines the dual functions of radionuclide imaging and treatment, and has been widely applied in the diagnosis and treatment of various tumors. Significant progress has been made in this field over the past few years, advancing tumor visualization for diagnostic assessment and precision treatment. However, issues such as inconsistent dose distribution between radionuclide imaging and therapy, short retention time of radionuclides, optimization of imaging radiation dose, and prediction of therapeutic dose remain prominent. This study introduces the current status and potential solutions to the above issues, including identifying different targets and probes, and screening patients sensitive to treatment, so as to improve the efficacy of radionuclide imaging and therapy. By modifying radionuclide imaging agents and using polymers or albumin conjugation, the retention time of radionuclides can be prolonged. Artificial intelligence is employed to reconstruct full-dose images or non-CT-attenuation-corrected images, thereby reducing imaging radiation dose. Machine learning models are utilized to optimize personalized therapeutic dose prediction. Overcoming these challenges can strongly promote the development of integrated radionuclide diagnosis and treatment.

Key words： Radionuclide; Integrated diagnosis and treatment; Dose optimization; Dose prediction; Artificial intelligence

Cite this article

HONG Yena , ZHANG Yü , SHI Kuangyu , LI Biao , GUO Rui . Issues and solutions in integrated radionuclide diagnosis and treatment[J]. Journal of Diagnostics Concepts & Practice, 2025 , 24(03) : 263 -267 . DOI: 10.16150/j.1671-2870.2025.03.004

References

[1] FUNKHOUSER J. Reinventing pharma: the theranostic revolution[J]. Curr Drug Discov, 2002(8):17-19.
[2] WEBER W A, BARTHEL H, BENGEL F, et al. What Is Theranostics?[J]. J Nucl Med, 2023, 64(5):669-670.
[3] 宋祥铭, 吕小迎, 兰晓莉. 放射性核素诊疗一体化临床研究进展[J]. 中国医学影像技术, 2024, 40(01):116-120.
  SONG X M, LV X Y, LAN X L. Clinical research progress of radionuclide theranostics[J]. Chin J Med Imaging Technol, 2024, 40(1):116-120.
[4] ZHANG S Q, WANG X K, GAO X, et al. Radiopharmaceuticals and their applications in medicine[J]. Signal Transduct Target Ther, 2025, 10(1):1.
[5] KARIMZADEH A, HECK M, TAUBER R, et al. 177Lu-PSMA-I&T for treatment of metastatic castration-resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers[J]. J Nucl Med, 2023, 64(3):402-409.
[6] RUZZEH S, ABDIKADIR A S, PAEZ D, et al. Therapeutic potential of FAPI RLT in oncology: a systematic review[J]. Theranostics, 2025, 15(9):4084-4100.
[7] ZHAO L, KANG F, PANG Y Z, et al. Fibroblast activation protein inhibitor tracers and their preclinical, translational, and clinical status in China[J]. J Nucl Med, 2024, 65(Suppl 1):4S-11S.
[8] ZHONG X, GUO J R, HAN X P, et al. Synthesis and preclinical evaluation of a novel FAPI-04 dimer for cancer theranostics[J]. Mol Pharm, 2023, 20(5):2402-2414.
[9] PANG Y Z, ZHAO L, FANG J Y, et al. Development of FAPI tetramers to improve tumor uptake and efficacy of FAPI radioligand therapy[J]. J Nucl Med, 2023, 64(9):1449-1455.
[10] ZBORALSKI D, HOEHNE A, BREDENBECK A, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy[J]. J Nucl Med, 2022, 49(11):3651-3667.
[11] PANG Y Z, ZHAO L, MENG T H, et al. PET imaging of fibroblast activation protein in various types of cancer using 68Ga-FAP-2286: comparison with 18F-FDG and 68Ga-FAPI-46 in a single-center, prospective study[J]. J Nucl Med, 2023, 64(3):386-394.
[12] MILLUL J, KOEPKE L, HARIDAS G R, et al. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides[J]. Eur J Nucl Med Mol Imaging, 2023, 50(10):3050-3061.
[13] ZHANG Q Y, HU Y Y, ZHOU C, et al. Reducing pediatric total-body PET/CT imaging scan time with multimodal artificial intelligence technology[J]. EJNMMI Phys, 2024, 11(1):1.
[14] LIU G B, HU P C, YU H J, et al. Ultra-low-activity total-body dynamic PET imaging allows equal performance to full-activity PET imaging for investigating kinetic metrics of 18F-FDG in healthy volunteers[J]. Eur J Nucl Med Mol Imaging, 2021, 48(8):2373-2383.
[15] TAN H, QI C, CAO Y Y, et al. Ultralow-dose [18F]FDG PET/CT imaging: demonstration of feasibility in dynamic and static images[J]. Eur Radiol, 2023, 33(7):5017-5027.
[16] CHEN W Q, LIU L, LI Y H, et al. Evaluation of pediatric malignancies using total-body PET/CT with half-dose [18F]-FDG[J]. Eur J Nucl Med Mol Imaging, 2022, 49(12):4145-4155.
[17] SARI H, TEIMOORISICHANI M, MINGELS C, et al. Quantitative evaluation of a deep learning-based framework to generate whole-body attenuation maps using LSO background radiation in long axial FOV PET scanners[J]. Eur J Nucl Med Mol Imaging, 2022, 49(13):4490-4502.
[18] MA R Y, HU J X, SARI H, et al. An encoder-decoder network for direct image reconstruction on sinograms of a long axial field of view PET[J]. Eur J Nucl Med Mol Ima-ging, 2022, 49(13):4464-4477.
[19] ILAN E, SANDSTROM M, WASSBERG C, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE[J]. J Nucl Med, 2015, 56(2):177-182.
[20] VIOLET J, JACKSON P, FERDINANDUS J, et al. Dosi-metry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes[J]. J Nucl Med, 2019, 60(4):517-523.
[21] STEINHELFER L, LUNGER L, CALA L, et al. Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy[J]. J Nucl Med, 2024, 65(1):79-84.
[22] PETERSON A B, WANG C, WONG K K, et al. 177Lu-DOTATATE theranostics: predicting renal dosimetry from pretherapy 68Ga-DOTATATE PET and clinical biomarkers[J]. Clin Nucl Med, 2023, 48(5):393-399.
[23] AKHAVANALLAF A, PETERSON A B, FITZPATRICK K, et al. The predictive value of pretherapy [68Ga]Ga-DOTA-TATE PET and biomarkers in [177Lu]Lu-PRRT tumor dosimetry[J]. Eur J Nucl Med Mol Imaging, 2023, 50(10):2984-2996.
[24] XUE S, GAFITA A, DONG C, et al. Application of machine learning to pretherapeutically estimate dosime-try in men with advanced prostate cancer treated with 177Lu-PSMA I & T therapy[J]. Eur J Nucl Med Mol Ima-ging, 2022, 49(12): 4064-4072.
[25] XUE S, GAFITA A, ZHAO Y, et al. Pre-therapy PET-based voxel-wise dosimetry prediction by characterizing intra-organ heterogeneity in PSMA-directed radiopharmaceutical theranostics[J]. Eur J Nucl Med Mol Imaging, 2024,51:3450-3460.
Options
Outlines

/

〈 〉